Back to Top Skip to main content Skip to sub-navigation

Army Announces FDA Clearance of Field Deployable TBI Blood Test

Military personnel standing in the snow preparing to fire a missile Soldiers from 1st/120th Field Artillery, Wisconsin National Guard, prepare to fire a M-777 Howitzer during Winter Strike 21 at Camp Grayling Maneuver Center, Michigan in Jan. 2021. Soon the Army should have a field-deployable means to detect and evaluate soldiers for TBI (Photo by: Air National Guard photo by Master Sgt. Dan Heaton).

Recommended Content:

Traumatic Brain Injury | Brain Injury Awareness Month | Brain Injury Awareness Toolkit | Brain Injury Awareness Toolkit | Brain Injury Awareness Toolkit | Brain Injury Awareness Toolkit | TBI Information | Brain Injury Awareness Toolkit

The U.S. Army Medical Materiel Development Activity, in partnership with Abbott, announced the U.S. Food and Drug Administration approval of the Abbott i-STAT™ Alinity™ Traumatic Brain Injury plasma assay, a rapid blood test for TBI in January.

Between 2000 and 2019, more than 400,000 service members experienced a TBI as a result of combat injuries and training accidents, as well as everyday activities such as sporting events.

Developing a field-deployable solution for the detection and evaluation of TBI among our wounded service members serving at home and deployed overseas has been a top priority for the Department of Defense for more than a decade.

"A rapid test for TBI is a critical addition to our downrange capability to care for the brain health of our most important weapon system, the Warfighter, and help maintain a high state of readiness across the Force," said Army Brig. Gen. Michael Talley, commanding general for the U.S. Army Medical Research and Development Command and Fort Detrick, Maryland.

The i-STAT Alinity TBI plasma assay can identify two brain-specific protein markers that rapidly appear in the blood following a TBI. This blood test will provide medical professionals with objective markers that indicate injury to the brain, as opposed to relying on subjective descriptions of the injury-causing incident, reduce the need for head Computed Tomography scans.

"A blood-based biomarker laboratory assay (blood test) for TBI will greatly enhance the ability of DOD medical personnel to objectively assess Service Members who have suffered a suspected TBI. The ability to avoid unnecessary evacuations for head CT scans could really impact the efficiency of TBI management,” said Dr. Krista Caudle, product manager for USAMMDA's Warfighter Brain Health Project Management Office.

The goal for initial implementation of the laboratory assay is to assist with the management of patients with a suspected TBI, particularly focusing on the areas where Service Members would be required to be evacuated from the operational setting to obtain a CT scan of the head. The overall objective is to have a logistically suitable, whole-blood, point-of-care TBI biomarker test with rapid turnaround time.

"The laboratory assay for TBI product development program is an example of how USAMRDC and private industry can share a common vision and achieve a common goal. Over the years, the program progressed through basic science studies at Walter Reed Army Institute of Research and USAMRDC's Combat Casualty Care Research Program, then into product development and clinical trials in USAMMDA, and ultimately U.S. FDA clearance," said Caudle.

The FDA-approved Banyan Biomarkers, Inc., Brain Trauma Indicator™, also funded by USAMMDA, laid the groundwork and served as a foundation for the i-STAT Alinity TBI plasma assay. The DOD partnered with Abbott to develop the TBI biomarkers into a field-deployable laboratory platform, which is an easy-to-use TBI cartridge utilized in the i-STAT Alinity device, the new version of the i-STAT 1 that is currently fielded by the U.S. Army. Recent user assessments have established preliminary suitability of the assay and device in operational laboratory settings for the Army. Future testing will confirm system suitability and enable fielding of this capability.

The laboratory assay for TBI point-of-care biomarker effort has been funded by the U.S. Army and is managed by USAMMDA's Warfighter Brain Health Project Management Office.

You also may be interested in...

Exiting an A-10C Thunderbolt

Photo
9/30/2016
U.S. Air Force Senior Airman Judith Bulkley, an electrical and environmental systems specialist deployed from the 23rd Aircraft Maintenance Squadron, Moody Air Force Base, Ga., exits an A-10C Thunderbolt II after performing an external power operations check on the aircraft at Kandahar Airfield, Afghanistan. Because service members in particular are often exposed to high noise levels, hearing protection is crucial, especially with a TBI. (U.S. Air Force photo by Tech. Sgt. Stephen Schester)

U.S. Air Force Senior Airman Judith Bulkley, an electrical and environmental systems specialist deployed from the 23rd Aircraft Maintenance Squadron, Moody Air Force Base, Ga., exits an A-10C Thunderbolt II after performing an external power operations check on the aircraft at Kandahar Airfield, Afghanistan. Because service members in particular are often exposed to high noise levels, hearing protection is crucial, especially with a TBI. (U.S. Air Force photo by Tech. Sgt. Stephen Schester)

Recommended Content:

Hearing Loss | Traumatic Brain Injury

The impact of traumatic brain injuries on community life

Photo
9/27/2016
A soldier at Joint Base Elmendorf-Richardson’s traumatic brain injury clinic in Alaska takes a cognitive hand-eye coordination test on a driving stimulator.

A soldier at Joint Base Elmendorf-Richardson’s traumatic brain injury clinic in Alaska takes a cognitive hand-eye coordination test on a driving stimulator.

Recommended Content:

Traumatic Brain Injury

Public Health Service Cmdr. Robin Toblin speaks at TBI Summit

Photo
9/21/2016
Public Health Service Cmdr. Robin Toblin with the Walter Reed Army Institute of Research was one of the more than 1,700 health care providers and policy makers from the Military Health System, the Department of Veterans Affairs, academia and commercial research companies who met in person and virtually during the recent Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury Summit held at the Defense Health Headquarters in Falls Church, Virginia. (DCoE photo by Terry Welch)

Public Health Service Cmdr. Robin Toblin with the Walter Reed Army Institute of Research was one of the more than 1,700 health care providers and policy makers from the Military Health System, the Department of Veterans Affairs, academia and commercial research companies who met in person and virtually during the recent Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury Summit held at the Defense Health Headquarters in Falls Church, Virginia. (DCoE photo by Terry Welch)

Recommended Content:

Traumatic Brain Injury
Showing results 1 - 3 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.